Hansa Biopharma
27,32 SEK +0,44%HC Andersen Capital saa maksun yhtiöltä Hansa Biopharma DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Lue lisääAnalyst
Viimeisimmät videot
Pörssikalenteri
Suurimmat omistajatLähde: Millistream Market Data AB
Omistaja | Osuus | Ääniä |
---|---|---|
Redmile Group | 18,3 % | 18,3 % |
Nexttobe | 4,1 % | 4,1 % |
Inderes Premium
Tämä sisältö on vain Inderes Premium -käyttäjille.
Hansa Biopharma AB: Hansa Biopharma interim report January-March 2024
Hansa Biopharma AB: Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.